RT Journal Article
SR Electronic
T1 Impact of remote-monitored home non-invasive ventilation on patient outcomes: a retrospective cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.04.11.24305702
DO 10.1101/2024.04.11.24305702
A1 Levey, Charlotte
A1 Manthe, Maureen
A1 Taylor, Anna
A1 Sahibqran, Maryam
A1 Walker, Eve
A1 McDowell, Grace
A1 Livingston, Eric
A1 Benjafield, Adam V.
A1 Carlin, Chris
YR 2024
UL http://medrxiv.org/content/early/2024/04/12/2024.04.11.24305702.abstract
AB Introduction Use of home non-invasive ventilation (NIV) to treat persistent hypercapnic respiratory failure in patients with stable chronic obstructive pulmonary disease (COPD) effectively reduces readmission rates and mortality compared with standard therapy. Traditional workflows around the initiation and management of NIV include elective admission for therapy initiation and frequent face-to-face clinic visits for follow-up, but use of telemedicine offers an alternative approach.Aim This retrospective cohort study evaluated the clinical efficacy and health resource use impact of a remote monitoring approach to the initiation and monitoring of home NIV.Methods Individuals with COPD, COPD-obstructive sleep apnoea or obesity-related respiratory failure who were started on remote-monitored home NIV from July 2016 to December 2020 were included. Data were obtained from electronic health records. The primary outcome was healthcare utilisation (hospital admissions and average number of bed days) in the 12 months after versus 12 months before starting NIV; secondary endpoints included 2-year survival and time to readmission, and blood gas analysis.Results In the 12 months after versus before NIV initiation, there was a significant reduction in the mean number of admissions (1.0±2.1 vs. 1.4±2.1; p<0.0001) and occupied bed days (9.6±26.8 vs. 17.2±27.5; p<0.0001); results were consistent across NIV indications. Time to first readmission (hazard ratio [HR] 2.11, 95% confidence interval [CI] 1.58–2.8; p<0.001) and time to death (HR 2.25, 95% CI 1.51–3.34; p<0.0001) were significantly worse in NIV non-users versus users, but did not differ by deprivation quintile. Blood gas analysis showed that NIV significantly reduced carbon dioxide pressure and bicarbonate compared with before NIV.Conclusions A technology-assisted service model for the remote initiation and monitoring of home NIV therapy for individuals with chronic hypercapnic respiratory failure was feasible, had a beneficial effect on healthcare utilisation and outcomes, and offset typical adverse relative survival outcomes associated with deprivation.What is already known on this topic When given at adequate pressures that ensure sufficient reduction in carbon dioxide pressure, home non-invasive ventilation (NIV) is an effective and well tolerated treatment for chronic hypercapnic respiratory failure in individuals with chronic obstructive pulmonary disease or obesity-related respiratory failure.What this study adds This study showed the feasibility and effectiveness of a remote monitoring approach to the initiation and management of home NIV therapy in a real-world setting.How this study might affect research, practice or policy As well as improving outcomes in appropriately selected individuals, the initiation and management of home NIV therapy using remote monitoring has the potential to improve workflow, equitably enhance access to and outcomes from treatment, and provide a rich continuous dataset that could facilitate derivation of actionable artificial intelligence insights to support proactive care interventions.Competing Interest StatementCL, MM, AT, MS, EW, GM and EL have no conflicts of interest to declare. AVB is an employee of ResMed. CC has received travel reimbursement and honoraria for conference and advisory board work from ResMed and Fisher & Paykel and unrestricted investigator-initiated grant funding from ResMed unrelated to this study.Funding StatementThe authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data access, handling and aggregation of de-identified data for this service evaluation and publication was approved by NHS Greater Glasgow and Clyde Caldicott GuardianI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData are available from the senior author on reasonable request.